Percheron Therapeutics has received a US FDA Safe to Proceed letter for Vanderbilt Health to begin an investigator-sponsored trial of HMBD-002 in combination with venetoclax and azacitidine. The early-stage study will target up to 20 patients with relapsed or refractory AML or AML with MDS.
- FDA clearance enables the Vanderbilt Health-led US trial to proceed
- HMBD-002 to be tested with venetoclax and azacitidine
- Study proposed to enrol up to 20 patients with relapsed or refractory disease
- Clinical trial material has been manufactured and released
- No efficacy, safety or commencement date disclosed
FDA Clearance Opens US Trial Pathway
Percheron Therapeutics Limited (ASX:PER) has cleared the most immediate regulatory hurdle for its lead oncology asset, with the US FDA allowing Vanderbilt Health to commence an investigator-sponsored trial of HMBD-002 in acute myeloid leukaemia and myelodysplastic syndrome.
The Safe to Proceed letter enables the multi-centre study to move forward in the United States. It is a regulatory milestone rather than a clinical result: the announcement contains no patient efficacy or safety data, and does not provide a firm trial commencement date.
HMBD-002 to Join Established AML Combination
Led by Dr Somedeb Ball of Vanderbilt Health, the proposed study will evaluate HMBD-002 alongside venetoclax and azacitidine in up to 20 patients with relapsed or refractory AML or AML with MDS. Its initial objective is dose-finding, including determining the optimal HMBD-002 dose for use with the two established therapies.
The trial advances the Vanderbilt AML trial launch, which was previously described as a multi-centre investigator-sponsored study targeting high-risk AML and MDS. Percheron will supply HMBD-002, provide technical assistance and financial grant support, while retaining full access to the resulting clinical data.
Manufacturing Ready as Company Awaits First Data
Percheron said clinical trial material has been manufactured and released, removing a further operational requirement before the study can begin. The company said the resulting data could inform future clinical development, regulatory interactions and partnering discussions, but the announcement does not disclose the value of its support or the study's detailed design.
The scientific rationale centres on VISTA, an immune checkpoint regulator that Percheron says is highly expressed in AML and has been associated with recurrence and treatment resistance. AML remains a severe disease, with the company citing an estimated 22,720 new US cases and 11,500 deaths in 2026, while five-year relative survival for patients diagnosed between 2016 and 2022 was 33.4%. Those figures explain the clinical need, but they do not predict HMBD-002's performance in patients.
Bottom Line?
The regulatory gate is open, but the investment case now turns on trial commencement, dose selection and whether the first patient data show a credible signal in a small, difficult-to-treat population.
Questions in the middle?
- When will Vanderbilt Health confirm the final study design and begin patient enrolment?
- Can HMBD-002 be dosed safely and effectively alongside venetoclax and azacitidine?
- Will early clinical data be strong enough to support a broader development program or partnering discussions?